Tg Therapeuticscmn (TGTX) 7.16 $TGTX
TG Therapeutics, Inc. Announces Data from TGR-1202 in Combination with Ibrutinib as well as Recaps Long-Term Safety and Efficacy Data of TGR-1202 in CLL and NHL at the 21st European Hematology Association Annual Congress
GlobeNewswire - Fri Jun 10, 8:15AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced data presented during the 21 Annual Congress of the European Hematology Association (EHA) being held in Copenhagen, Denmark. These presentations include long term follow-up data of TGR-1202, the Company's once daily PI3K delta inhibitor, both alone and in combination with TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, as well as data presented for the first time from a Phase I/Ib study of TGR-1202 in combination with ibrutinib in patients with relapsed/refractory CLL or MCL.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 09, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference being held at the Grand Hyatt in New York, NY. The presentation is scheduled to take place on Friday June 10, 2016 at 10:00am PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces First Patient Enrolled in the Registration-Directed UNITY-DLBCL Phase 2b Trial
GlobeNewswire - Tue Jun 07, 6:30AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the enrollment of its first patient in its registration-directed UNITY-DLBCL Phase 2b clinical study evaluating TG-1101, the Company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with TGR-1202, the Company's orally available PI3K delta inhibitor, as well as TGR-1202 alone, in patients with previously treated Diffuse Large B-Cell Lymphoma (DLBCL).
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Mon Jun 06, 8:00AM CDT
High response rates observed across CLL, DLBCL & indolent NHL
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Thu Jun 02, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today recapped the schedule of data presentations at the 52 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 3 - 7, 2016, at McCormick Place in Chicago, Illinois.
TGTX: 7.16 (-0.23)
TG Therapeutics Enters into a Global Collaboration to Develop and Commercialize Novel BET Inhibitors Developed by Jubilant Biosys for the Treatment of Hematological Malignancies
GlobeNewswire - Fri May 27, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that as part of a broader agreement with Jubilant Biosys ("Jubilant"
, an Indian biotechnology company, TG Therapeutics entered into a sub-license agreement with Checkpoint Therapeutics, Inc. ("Checkpoint" , a Fortress Biotech company, to develop and commercialize Jubilant's novel BET inhibitor program in the field of hematological malignancies. Checkpoint will develop and commercialize these small molecule inhibitors in solid tumors. The BET inhibitor program is the subject of an exclusive, worldwide license agreement pursuant to which Checkpoint in-licensed from Jubilant a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 21st European Hematology Association Annual Congress
GlobeNewswire - Fri May 20, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that updated data has been selected for presentation at the upcoming 21 European Hematology Association (EHA) Annual Congress, to be held from June 9 - 12, 2016 in Copenhagen, Denmark.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Clinical Data Presentation at the Upcoming 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Wed May 18, 4:15PM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that updated data has been selected for presentation at the upcoming 52 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 3 - 7, 2016, at McCormick Place in Chicago, Illinois.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Tue May 10, 3:00PM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the first quarter ended March 31, 2016 and recent company developments.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. to Host Conference Call on First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Mon May 09, 6:30AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Tuesday, May 10, 2016 at 4:30pm ET to discuss results for the first quarter of 2016 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Launches First Clinical Trial in Multiple Sclerosis (MS) for TG-1101 (Ublituximab)
GlobeNewswire - Tue May 03, 6:30AM CDT
Phase 2 study commenced to determine optimal dosing regimen in Relapsing MS patients
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Pre-Clinical Data Presentation on TGR-1202 Demonstrating Differentiated Effects on T-Cells
GlobeNewswire - Mon Apr 18, 6:35AM CDT
Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2016 compares TGR-1202 to other PI3K-delta inhibitors, providing preliminary mechanism for differentiated clinical safety observed to date
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Issuance of Composition of Matter Patent for TG-1101 in the United States
GlobeNewswire - Wed Apr 13, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for the composition of matter of TG-1101, the Company's novel, glycoengineered monoclonal antibody. The patent, U.S. Patent No. 9,234,045 specifically covers the composition of TG-1101, and its use for treating various forms of CD20 expressing leukemia and lymphoma, including chronic lymphocytic leukemia (CLL) and various types of non-Hodgkin's lymphoma, including follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL).
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Pre-Clinical Data Presentation on TGR-1202 at the 2016 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Thu Mar 17, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that preclinical data describing the differential regulation of human T-cells by TGR-1202 was selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2016, to be held April 16 - 20, 2016 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The data, which was developed as part of an ongoing research collaboration with the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL, compares TGR-1202 with the PI3K-delta inhibitors idelalisib and duvelisib in in-vitro models assessing the impact on T-cell subsets.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. to Present at the 28th Annual ROTH Conference
GlobeNewswire - Fri Mar 11, 3:30PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the 28 Annual ROTH Conference, being held at the Ritz Carlton in Laguna Niguel, CA. The presentation is scheduled to take place on Tuesday March 15, 2016 at 3:30pm PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
TGTX: 7.16 (-0.23)
TG Therapeutics reports 4Q loss
Automated Insights - Mon Mar 07, 3:39PM CST
NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Monday reported a loss of $17.6 million in its fourth quarter.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2015 Financial Results and Business Update
GlobeNewswire - Mon Mar 07, 3:00PM CST
Ended 2015 in a Strong Financial Position, With More Than $100 Million in Cash and Investments
TGTX: 7.16 (-0.23)
Investor Calendar Invites You to the TG Therapeutics, Inc. Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Monday, March 7, 2016
ACCESSWIRE - Mon Mar 07, 7:00AM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / TG Therapeutics, Inc. (NASDAQ: TGTX) will host a live conference call and webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held today, Monday, March 7, 2016 at 4:30 PM Eastern Time.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. to Present at Upcoming Investment Conferences
GlobeNewswire - Mon Mar 07, 6:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced its participation at two upcoming investment conferences. Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, is scheduled to present tomorrow Tuesday, March 8, 2016 at 11:35am ET, at the Raymond James & Associates' 37 Annual Institutional Investors Conference, being held at the JW Marriott Grande Lakes in Orlando, Florida. Michael Weiss is also scheduled to present on Wednesday, March 9, 2016 at 9:20am ET at the Cowen and Company 36 Annual Health Care Conference, being held at the Marriott Copley Place.
TGTX: 7.16 (-0.23)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfgg5w/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hutchison MediPharma Limited - ImmunoGen, Inc. - Immunomedics, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - Lymphocyte Activation Technologies, S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rf...ed_chronic
CYCC: 5.95 (-0.14), ABBV: 61.00 (+0.25), INFI: 4.81 (-0.23), JUNO: 42.98 (-2.55), IMMU: 3.05 (-0.08), PTLA: 26.38 (-0.46), EBS: 42.30 (-1.19), INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), TGTX: 7.16 (-0.23), BMY: 72.65 (-0.08), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), CELGZ: 1.46 (-0.04), KPTI: 8.53 (-0.60), NVS: 78.94 (-1.57)
TG Therapeutics, Inc. Announces Data from TGR-1202 in Combination with Ibrutinib as well as Recaps Long-Term Safety and Efficacy Data of TGR-1202 in CLL and NHL at the 21st European Hematology Association Annual Congress
GlobeNewswire - Fri Jun 10, 8:15AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced data presented during the 21 Annual Congress of the European Hematology Association (EHA) being held in Copenhagen, Denmark. These presentations include long term follow-up data of TGR-1202, the Company's once daily PI3K delta inhibitor, both alone and in combination with TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, as well as data presented for the first time from a Phase I/Ib study of TGR-1202 in combination with ibrutinib in patients with relapsed/refractory CLL or MCL.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 09, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference being held at the Grand Hyatt in New York, NY. The presentation is scheduled to take place on Friday June 10, 2016 at 10:00am PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces First Patient Enrolled in the Registration-Directed UNITY-DLBCL Phase 2b Trial
GlobeNewswire - Tue Jun 07, 6:30AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the enrollment of its first patient in its registration-directed UNITY-DLBCL Phase 2b clinical study evaluating TG-1101, the Company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with TGR-1202, the Company's orally available PI3K delta inhibitor, as well as TGR-1202 alone, in patients with previously treated Diffuse Large B-Cell Lymphoma (DLBCL).
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Mon Jun 06, 8:00AM CDT
High response rates observed across CLL, DLBCL & indolent NHL
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Thu Jun 02, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today recapped the schedule of data presentations at the 52 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 3 - 7, 2016, at McCormick Place in Chicago, Illinois.
TGTX: 7.16 (-0.23)
TG Therapeutics Enters into a Global Collaboration to Develop and Commercialize Novel BET Inhibitors Developed by Jubilant Biosys for the Treatment of Hematological Malignancies
GlobeNewswire - Fri May 27, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that as part of a broader agreement with Jubilant Biosys ("Jubilant"
, an Indian biotechnology company, TG Therapeutics entered into a sub-license agreement with Checkpoint Therapeutics, Inc. ("Checkpoint" , a Fortress Biotech company, to develop and commercialize Jubilant's novel BET inhibitor program in the field of hematological malignancies. Checkpoint will develop and commercialize these small molecule inhibitors in solid tumors. The BET inhibitor program is the subject of an exclusive, worldwide license agreement pursuant to which Checkpoint in-licensed from Jubilant a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment. TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 21st European Hematology Association Annual Congress
GlobeNewswire - Fri May 20, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that updated data has been selected for presentation at the upcoming 21 European Hematology Association (EHA) Annual Congress, to be held from June 9 - 12, 2016 in Copenhagen, Denmark.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Clinical Data Presentation at the Upcoming 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Wed May 18, 4:15PM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that updated data has been selected for presentation at the upcoming 52 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 3 - 7, 2016, at McCormick Place in Chicago, Illinois.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Tue May 10, 3:00PM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the first quarter ended March 31, 2016 and recent company developments.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. to Host Conference Call on First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Mon May 09, 6:30AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Tuesday, May 10, 2016 at 4:30pm ET to discuss results for the first quarter of 2016 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Launches First Clinical Trial in Multiple Sclerosis (MS) for TG-1101 (Ublituximab)
GlobeNewswire - Tue May 03, 6:30AM CDT
Phase 2 study commenced to determine optimal dosing regimen in Relapsing MS patients
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Pre-Clinical Data Presentation on TGR-1202 Demonstrating Differentiated Effects on T-Cells
GlobeNewswire - Mon Apr 18, 6:35AM CDT
Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2016 compares TGR-1202 to other PI3K-delta inhibitors, providing preliminary mechanism for differentiated clinical safety observed to date
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Issuance of Composition of Matter Patent for TG-1101 in the United States
GlobeNewswire - Wed Apr 13, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for the composition of matter of TG-1101, the Company's novel, glycoengineered monoclonal antibody. The patent, U.S. Patent No. 9,234,045 specifically covers the composition of TG-1101, and its use for treating various forms of CD20 expressing leukemia and lymphoma, including chronic lymphocytic leukemia (CLL) and various types of non-Hodgkin's lymphoma, including follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL).
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Pre-Clinical Data Presentation on TGR-1202 at the 2016 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Thu Mar 17, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that preclinical data describing the differential regulation of human T-cells by TGR-1202 was selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2016, to be held April 16 - 20, 2016 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The data, which was developed as part of an ongoing research collaboration with the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL, compares TGR-1202 with the PI3K-delta inhibitors idelalisib and duvelisib in in-vitro models assessing the impact on T-cell subsets.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. to Present at the 28th Annual ROTH Conference
GlobeNewswire - Fri Mar 11, 3:30PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the 28 Annual ROTH Conference, being held at the Ritz Carlton in Laguna Niguel, CA. The presentation is scheduled to take place on Tuesday March 15, 2016 at 3:30pm PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
TGTX: 7.16 (-0.23)
TG Therapeutics reports 4Q loss
Automated Insights - Mon Mar 07, 3:39PM CST
NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Monday reported a loss of $17.6 million in its fourth quarter.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2015 Financial Results and Business Update
GlobeNewswire - Mon Mar 07, 3:00PM CST
Ended 2015 in a Strong Financial Position, With More Than $100 Million in Cash and Investments
TGTX: 7.16 (-0.23)
Investor Calendar Invites You to the TG Therapeutics, Inc. Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Monday, March 7, 2016
ACCESSWIRE - Mon Mar 07, 7:00AM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / TG Therapeutics, Inc. (NASDAQ: TGTX) will host a live conference call and webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held today, Monday, March 7, 2016 at 4:30 PM Eastern Time.
TGTX: 7.16 (-0.23)
TG Therapeutics, Inc. to Present at Upcoming Investment Conferences
GlobeNewswire - Mon Mar 07, 6:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced its participation at two upcoming investment conferences. Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, is scheduled to present tomorrow Tuesday, March 8, 2016 at 11:35am ET, at the Raymond James & Associates' 37 Annual Institutional Investors Conference, being held at the JW Marriott Grande Lakes in Orlando, Florida. Michael Weiss is also scheduled to present on Wednesday, March 9, 2016 at 9:20am ET at the Cowen and Company 36 Annual Health Care Conference, being held at the Marriott Copley Place.
TGTX: 7.16 (-0.23)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfgg5w/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hutchison MediPharma Limited - ImmunoGen, Inc. - Immunomedics, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - Lymphocyte Activation Technologies, S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rf...ed_chronic
CYCC: 5.95 (-0.14), ABBV: 61.00 (+0.25), INFI: 4.81 (-0.23), JUNO: 42.98 (-2.55), IMMU: 3.05 (-0.08), PTLA: 26.38 (-0.46), EBS: 42.30 (-1.19), INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), TGTX: 7.16 (-0.23), BMY: 72.65 (-0.08), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), CELGZ: 1.46 (-0.04), KPTI: 8.53 (-0.60), NVS: 78.94 (-1.57)
